These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38995265)

  • 1. Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.
    Forster M; Brana I; Pousa AL; Doger B; Roxburgh P; Bajaj P; Peguero J; Krebs M; Carcereny E; Patel G; Mueller C; Brignone C; Triebel F
    Clin Cancer Res; 2024 Sep; 30(17):3726-3734. PubMed ID: 38995265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
    Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
    Dzienis M; Cundom J; Fuentes CS; Spreafico A; Nordlinger M; Pastor AV; Alesi E; Neki A; Fung AS; Figueiredo Lima IP; Oppelt P; da Cunha Junior GF; Burtness B; Franke FA; Tseng JE; Joshi A; McCarthy J; Swaby R; Sidi Y; Gumuscu B; Naicker N; de Castro G
    J Clin Oncol; 2024 Sep; 42(25):2989-2999. PubMed ID: 39038265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
    Cho BC; Braña I; Cirauqui B; Aksoy S; Couture F; Hong RL; Miller WH; Chaves-Conde M; Teixeira M; Leopold L; Munteanu M; Ge JY; Swaby RF; Hughes BGM
    BMC Cancer; 2024 Jul; 23(Suppl 1):1254. PubMed ID: 39054467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
    Adkins D; Ley JC; Liu J; Oppelt P
    Lancet Oncol; 2024 Jul; 25(7):888-900. PubMed ID: 38851207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
    Iwaki S; Kadowaki S; Honda K; Narita Y; Masuishi T; Taniguchi H; Ando M; Muro K; Sawabe M; Suzuki H; Nishikawa D; Beppu S; Terada H; Kishikawa T; Kawakita D; Hanai N
    Int J Clin Oncol; 2024 Jun; 29(6):764-770. PubMed ID: 38555323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.
    Atkinson V; Khattak A; Haydon A; Eastgate M; Roy A; Prithviraj P; Mueller C; Brignone C; Triebel F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33219094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.
    Krebs MG; Forster M; Majem M; Peguero J; Iams W; Clay T; Roxburgh P; Doger B; Bajaj P; Barba A; Perera S; Mueller C; Triebel F
    JTO Clin Res Rep; 2024 Nov; 5(11):100725. PubMed ID: 39403626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
    Jackovich A; Gitlitz BJ; Tiu-Lim JWW; Duddalwar V; King KG; El-Khoueiry AB; Thomas JS; Tsao-Wei D; Quinn DI; Gill PS; Nieva JJ
    Oncotarget; 2024 Jul; 15():444-458. PubMed ID: 38985143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
    Saba NF; Chaudhary R; Kirtane K; Marra A; Ekpenyong A; McCook-Veal A; Schmitt NC; Gross JH; Patel MR; Remick J; Bates JE; McDonald MW; Rudra SF; Stokes WA; Biernacki M; Song X; Slebos RJC; Liu Y; Steuer CE; Shin DM; Teng Y; Chung CH
    Clin Cancer Res; 2024 Oct; 30(20):4601-4608. PubMed ID: 39167623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phaseⅡstudy].
    Chen XR; Xie ZC; Lu HZ; Yang JL; Gui L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):321-328. PubMed ID: 38599639
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
    Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
    Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    Algazi A; Papadopoulos KP; Tsai F; Hansen AR; Angra N; Das M; Sheth S; Siu LL
    ESMO Open; 2024 Aug; 9(8):103646. PubMed ID: 39043009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.